Selection of our poster presentations at ISPOR | November 6 – 9, 2022 at Vienna, Austria
Background
While health technologies are targeted at improving patient health-related quality of life (HRQoL), it is increasingly acknowledged that treatments can also benefit individuals within the patient’s network, such as caring and noncaring family members. The 2022 National Institute for Health and Care Excellence (NICE) methods guide1 states that health effects in others,
particularly carers, should be considered when relevant. A review of NICE appraisals by Pennington (2020) 2 showed that in practice the inclusion of carer HRQoL in cost-utility analysis (CUA) is rare. We aimed to establish the use of carer HRQoL in NICE appraisals since 2019.
VIEW POSTER and read main findings
_____________________________________________________________________________________________________________________
Objective
Proton beam therapy (PBT) may deliver more precise treatment compared with conventional radiotherapy for patients with cancer. While this innovation entails investment costs, the information about the treatment costs per patient, especially during the start-up phase, is limited. This study aims to calculate the costs for PBT at a single center during the start-up phase in the Netherlands.
VIEW POSTER and read main findings
_____________________________________________________________________________________________________________________
Objective
Heart failure is a leading cause of hospitalization and mortality worldwide, and 242,300 cases were reported in 2018 in the Netherlands alone. Dapagliflozin is a SGLT2 inhibitor registered for treatment for chronic symptomatic heart failure with reduced ejection fraction, among other indications. Aim of this study was to estimate the cost-effectiveness of dapagliflozin in Dutch patients with symptomatic chronic heart failure and a reduced ejection fraction (HFrEF) when adding dapagliflozin to standard of care (SoC). Dapagliflozin and SoC were compared to SoC alone. The SoC was based on the background treatment as observed in the DAPA-HF trial, which was in accordance with international and national guidelines for SoC for HF treatment.
VIEW POSTER and read main findings
_____________________________________________________________________________________________________________________
Aim
Explore the perspectives of patients and neurologists on the use of AI and remote monitoring for detection of advanced PD.
VIEW POSTER and read main findings
_____________________________________________________________________________________________________________________